Clinical trials
Cardiac Magnetic Resonance Imaging clinical trials
Below are recruiting cardiac magnetic resonance imaging clinical trials, each written for real people, not researchers. We’re tracking 289 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03942328RecruitingPhase 1/Phase 2
Immune cell vaccine plus checkpoint treatment after liver radiation
This trial tests a combination of a personalized immune cell treatment (made from your own cells) and a pneumococcal vaccine along with an “immune checkpoint” drug after high-dose radiation for certain unresectable liver cancers. The goal is to help your immune system better attack the cancer and to see how safe and effective this approach is.
Rochester, MinnesotaAges 18 years+ - NCT06330805RecruitingPhase 2
Comparing heart effects of two hormone therapies for prostate cancer
This trial compares two hormone therapies, relugolix and leuprolide, to see which one is better for your heart health in men with prostate cancer. It's for men with a specific type of prostate cancer that is not yet advanced.
Columbus, OhioAges 18 years+ - NCT06336902RecruitingPhase 1
Immunotherapy plus fasting diet and vitamin C for KRAS-mutated colorectal cancer
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) plus a fasting-mimicking diet and high-dose vitamin C for people with a specific type of advanced colorectal cancer (KRAS-mutated). It aims to see if this approach can help when standard treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT06399419RecruitingPhase 1
Study of CBM588 with immunotherapy for advanced kidney cancer
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Duarte, CaliforniaAges 18 years+ - NCT06410248RecruitingPhase 1
Triapine and temozolomide for recurrent glioblastoma
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06442475RecruitingPhase 2
Low-dose mosunetuzumab for untreated indolent B-cell lymphoma
This trial tests a low dose of the drug mosunetuzumab for people with slow-growing B-cell lymphomas (follicular lymphoma or marginal zone lymphoma) who have not had any previous treatment. It aims to see if this drug can help control the disease with fewer side effects.
Seattle, WashingtonAges 18 years+ - NCT06465316RecruitingPhase 1
Teclistamab plus iberdomide for relapsed multiple myeloma
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
Phoenix, ArizonaAges 18 years+ - NCT06470282RecruitingPhase 1/Phase 2
Drug combo plus radiation for muscle-invasive bladder cancer
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
San Francisco, CaliforniaAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Tucson, ArizonaAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT06504381RecruitingPhase 1/Phase 2
DB107 and radiation therapy for high-grade glioma
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06525766RecruitingPhase 2
Adaptive capecitabine for advanced ER+ HER2- breast cancer
This trial tests a personalized schedule of capecitabine (a chemo pill) for metastatic breast cancer that is ER+ and HER2-. The goal is to see if adjusting the dose based on your tumor response can help control the cancer while reducing side effects.
Scottsdale, ArizonaAges 18 years+ - NCT06528769RecruitingPhase 2
ATRA and immunotherapy for advanced leiomyosarcoma
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Columbus, OhioAges 18 years+ - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06622005RecruitingPhase 1
Testing SX-682 with standard drugs for relapsed myeloma
This trial tests a new drug called SX-682 added to a standard three-drug combination (carfilzomib, daratumumab, dexamethasone) for people with multiple myeloma that has returned or stopped responding to earlier treatments. The goal is to see if adding SX-682 can help control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06688916Recruiting
Body awareness after spinal cord injury
This study examines how people with spinal cord injury experience their body and sense of self. You will answer questionnaires and may have an MRI scan of your brain while parts of your body are touched, to see how your brain reacts.
Nottwil, Canton of LucerneAges 18–65 - NCT06696768RecruitingPhase 1
New drug plus chemo for advanced colorectal cancer
This trial tests a new targeted drug (CA-4948) plus a standard chemotherapy combo (FOLFOX and bevacizumab) for people with colorectal cancer that has spread. The goal is to see if this combination works better than standard treatment alone.
Gainesville, FloridaAges 18 years+ - NCT04765150Recruiting
AI helps classify prostate cancer using MRI images
This trial studies whether a computer (AI) can better sort MRI results to improve prostate cancer diagnosis or classification. You may benefit by getting your multi-part MRI looked at in a new, more precise way, while helping researchers refine decision-making.
Los Angeles, CaliforniaAges 18 years+ - NCT06043713RecruitingPhase 1
T-cell therapy for KRAS G12V solid tumors
This trial tests a personalized T-cell therapy designed to recognize and attack cancer cells with a specific KRAS G12V mutation. It is for people with metastatic solid tumors that have this mutation and a specific immune type (HLA-A*11:01).
Seattle, WashingtonAges 18 years+ - NCT06712810RecruitingPhase 1
Q702 for blood cancers and histiocytic disorders
This study tests an experimental pill called Q702 for people with certain blood cancers and related disorders (like histiocytoses, myelofibrosis, and lymphomas) that have not responded to standard treatments. It aims to see if Q702 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06735690RecruitingEarly Phase 1
Immune cells plus vaccine after stem cell transplant for leukemia
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
Duarte, CaliforniaAges 18 years+
Hear when a new Cardiac Magnetic Resonance Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiac magnetic resonance imaging?
- Yes. Clin2 currently lists 289 recruiting cardiac magnetic resonance imaging studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiac magnetic resonance imaging trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiac magnetic resonance imaging trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.